The Supreme Court halted new restrictions on mifepristone Monday, preserving access to mail-order dispensing of the abortion drug through Thursday evening. Justice Samuel Alito extended a temporary stay he had issued a week earlier, responding to requests from manufacturers Danco Laboratories and GenBioPro seeking to maintain teleprescribing capabilities.
The reprieve buys time for pharmacies, telehealth providers, and clinicians navigating the ongoing legal battle over how the pill reaches patients. Mail-order access and remote prescribing remain available under the freeze.
The case centers on Biden administration policies that loosened rules around mifepristone. The federal government removed a requirement that patients meet a doctor in person before receiving the medication and expanded overall access to the drug.
Anti-abortion groups have pushed to reverse those changes. Their argument gained traction when the 5th U.S. Circuit Court of Appeals recently sided with Louisiana in a challenge to the Biden rules. Louisiana contended the expanded access undermined its own laws on fetal protection and forced the state to spend Medicaid dollars on emergency care for women it says were harmed by the pill.
The Supreme Court's extension delays any immediate enforcement of restrictions but leaves the underlying legal questions unresolved. The temporary stay expires Thursday at 5 p.m., setting another potential flashpoint in the escalating fight over mifepristone access.
Author James Rodriguez: "The Court is buying time without deciding the case, which means we'll likely see another filing and another emergency order before the week ends."
Comments